A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group
- PMID: 1674105
- DOI: 10.1056/NEJM199105303242204
A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group
Abstract
Background: In primary biliary cirrhosis the hepatic lesions may result, at least in part, from the intracellular accumulation of potentially toxic endogenous bile acids. Preliminary work suggests that the administration of ursodiol (also called ursodeoxycholic acid), a hydrophilic bile acid without hepatotoxicity, leads to improvement in the condition of patients with primary biliary cirrhosis.
Methods: We conducted a two-year, multicenter, double-blind trial to compare the efficacy of ursodiol with that of placebo. Patients with biopsy-proved primary biliary cirrhosis were randomly assigned to receive either ursodiol (13 to 15 mg per kilogram of body weight per day) (n = 73) or placebo (n = 73). Treatment failure was defined as a doubling of bilirubin levels to more than 70 mumol per liter or the occurrence of a severe complication (ascites or variceal bleeding) or an adverse reaction.
Results: Treatment failed in 6 patients in the ursodiol group, as compared with 13 in the placebo group (P less than 0.01 by Cox regression model). A single patient in each group withdrew because of minor adverse effects. After two years of treatment, the proportion of patients with clinically overt disease decreased only in the ursodiol group (P less than 0.02). The patients treated with ursodiol had significant improvements in serum levels of bilirubin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyltransferase, cholesterol, and IgM (all P less than 0.001); the antimitochondrial-antibody titer (P less than 0.01); and the Mayo risk score (P less than 0.001). Follow-up analysis of 95 liver-biopsy specimens showed a significant improvement in the mean histologic score (P less than 0.002) and in all the characteristic histologic features except fibrosis only in the group given ursodiol.
Conclusions: Ursodiol is a safe and effective treatment for primary biliary cirrhosis.
Similar articles
-
Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group.N Engl J Med. 1994 May 12;330(19):1342-7. doi: 10.1056/NEJM199405123301903. N Engl J Med. 1994. PMID: 8152446 Clinical Trial.
-
Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis.Am J Gastroenterol. 1990 Jan;85(1):15-23. Am J Gastroenterol. 1990. PMID: 1967512
-
The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis.Hepatology. 1994 May;19(5):1149-56. Hepatology. 1994. PMID: 8175136 Clinical Trial.
-
[Treatment of cholestatic liver disease].Rev Med Chir Soc Med Nat Iasi. 2003 Oct-Dec;107(4):733-6. Rev Med Chir Soc Med Nat Iasi. 2003. PMID: 14756010 Review. Romanian.
-
Treatment of chronic liver disease with ursodeoxycholic acid.J Int Med Res. 1990 Nov-Dec;18(6):497-505. doi: 10.1177/030006059001800608. J Int Med Res. 1990. PMID: 2292332 Review.
Cited by
-
Incidence, mortality, and predictive factors of hepatocellular carcinoma in primary biliary cirrhosis.Gastroenterol Res Pract. 2013;2013:168012. doi: 10.1155/2013/168012. Epub 2013 Feb 25. Gastroenterol Res Pract. 2013. PMID: 23533384 Free PMC article.
-
Is there a role for cyclophilin inhibitors in the management of primary biliary cirrhosis?Viruses. 2013 Jan 24;5(2):423-38. doi: 10.3390/v5020423. Viruses. 2013. PMID: 23348060 Free PMC article. Review.
-
Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH).Dig Dis Sci. 2007 Oct;52(10):2512-9. doi: 10.1007/s10620-006-9631-1. Epub 2007 Apr 3. Dig Dis Sci. 2007. PMID: 17404856
-
Prediction of Transplant-Free Survival through Albumin-Bilirubin Score in Primary Biliary Cholangitis.J Clin Med. 2019 Aug 19;8(8):1258. doi: 10.3390/jcm8081258. J Clin Med. 2019. PMID: 31430975 Free PMC article.
-
Treatment of Fatigue in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis.Dig Dis Sci. 2019 Aug;64(8):2338-2350. doi: 10.1007/s10620-019-5457-5. Epub 2019 Jan 10. Dig Dis Sci. 2019. PMID: 30632051
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical